LXRX vs. VSTM, VNDA, XOMA, EBS, MACK, RIGL, RGLS, RZLT, OPK, and INVA
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Emergent BioSolutions (EBS), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Rezolute (RZLT), OPKO Health (OPK), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -8,311.12%. Verastem's return on equity of -108.54% beat Lexicon Pharmaceuticals' return on equity.
Verastem currently has a consensus price target of $28.79, suggesting a potential upside of 142.30%. Lexicon Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 199.40%. Given Verastem's higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Verastem.
In the previous week, Verastem had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 2 mentions for Verastem and 0 mentions for Lexicon Pharmaceuticals. Verastem's average media sentiment score of 0.69 beat Lexicon Pharmaceuticals' score of 0.51 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Verastem received 130 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 65.17% of users gave Verastem an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
Verastem has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Verastem has higher revenue and earnings than Lexicon Pharmaceuticals. Verastem is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
88.4% of Verastem shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 2.2% of Verastem shares are owned by insiders. Comparatively, 4.5% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Verastem and Lexicon Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
